[ad_1]
"It is a new oral therapy that has been shown to be effective in MS patients, allowing the disease to be transmitted and slowing down its disabling effects without the need to administer constantly treat or monitor it frequently, "said Luciano Rossetti, Vice President Pharmaceutical Merck.
The therapy, he explained, is short-lived because it is reduced to two short-term oral treatments for four years, which means fewer days of treatment.
Multiple sclerosis is a chronic autoimmune disease. and inflammatory, where the body's immune system attacks the myelin, an insulating coating around the nerve cells of the brain and / or spinal cord taking it to a foreign substance.
This is a previously incurable condition that affects more than 2.3 million people worldwide, 85% of whom have a recurrent form of the disease.
In Latin In America, this figure represents between 50,000 and 100,000 patients, while in Mexico, about 20,000 people are affected by this disease.
Merck Pharmaceutical created this drug, known as cladribine tablets, specifically for the treatment of a very active REMR, with frequent outbreaks and progression of disability.
However, it will not be a drug of choice, nor a drug of choice.
"This new treatment is considered a drug of choice. High efficiency because it manages to significantly reduce the number of outbreaks and slow the progression of disability, "said the global director and development of Merck.
According to Rossetti, this new drug is the first modifier of disease that provides four years of control of this disease with a maximum oral dose of 20 days in the first two years.
In addition to canning In addition to the disease, patients will have the opportunity to have this treatment shorter, which will also result in pocket savings.
"One of the main effects of this disease is economic because of high drug costs, relapse and progression of disability According to Rossetti,
It is estimated that 70% of multiple sclerosis cases occur between the ages of 20 and 40, affecting the quality of life of young adults at the most productive stage of their lives.
In addition, 25% of patients will need a wheelchair 15 years after diagnosis.
In addition, the SMPR can become disabling for the patient and leave him unemployed. because about 50% of patients with this disease lose their job between 3 and 10 years after diagnosis.
Rossetti badured that the effectiveness of this new treatment had been demonstrated. in three clinical trials involving 2,700 patients.
"In patients with high pathological activity, CLARITY two-year phase III clinical trial badyzes showed that cladribine tablets reduced the annualized rate of outbreaks by 67% and the risk of progression. confirmed 82% 82% EDSS at the end of the study compared to placebo, "he explained.
Among the side effects of this new drug, there is a reduction in the number of lymphocytes. , infections and increased risk of developing cancer.
This drug is contraindicated to pregnant women and persons with active chronic infection, eg tuberculosis or hepatitis, HIV, severe or moderate kidney or liver disease.
Women of childbearing potential should avoid pregnancy during treatment and at least 6 months after the last dose of the second year.
Rossetti badured that the agreement has already been approved in more than 40 countries, including Canada, Argentina, Chile and part of the European Union. It will be signed in the coming months in Mexico and Latin America. EFE
[ad_2]
Source link
